|
2020-03-18 |
2020-03-17 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
Dirigeant
|
2 288
-100.0%
44,25
101 244 USD
|
2 288
-100.0%
|
44,25
|
101 244 USD
|
|
|
2020-03-18 |
2020-03-16 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
Dirigeant
|
10 595
-59.8%
45,16
478 521 USD
|
10 595
-59.8%
|
45,16
|
478 521 USD
|
|
|
2020-02-20 |
2020-02-18 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
Dirigeant
|
10 595
-59.8%
46,61
493 850 USD
|
10 595
-59.8%
|
46,61
|
493 850 USD
|
|
|
2020-01-21 |
2020-01-17 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
|
2 285
-50.0%
47,02
107 441 USD
|
2 285
-50.0%
|
47,02
|
107 441 USD
|
|
|
2020-01-16 |
2020-01-15 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10 595
-59.8%
46,95
497 441 USD
|
10 595
-59.8%
|
46,95
|
497 441 USD
|
|
|
2019-12-18 |
2019-12-17 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
Dirigeant
|
10 000
-61.6%
47,08
470 821 USD
|
10 000
-61.6%
|
47,08
|
470 821 USD
|
|
|
2019-12-18 |
2019-12-17 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
Dirigeant
|
2 285
-33.3%
47,08
107 568 USD
|
2 285
-33.3%
|
47,08
|
107 568 USD
|
|
|
2019-12-18 |
2019-12-16 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
Dirigeant
|
10 595
-59.8%
47,23
500 351 USD
|
10 595
-59.8%
|
47,23
|
500 351 USD
|
|
|
2019-11-18 |
2019-11-15 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
Dirigeant
|
10 595
-59.8%
46,66
494 319 USD
|
10 595
-59.8%
|
46,66
|
494 319 USD
|
|
|
2019-11-18 |
2019-11-14 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
Dirigeant
|
10 000
-61.6%
46,68
466 808 USD
|
10 000
-61.6%
|
46,68
|
466 808 USD
|
|
|
2019-10-17 |
2019-10-17 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
|
2 285
-25.0%
46,70
106 710 USD
|
2 285
-25.0%
|
46,70
|
106 710 USD
|
|
|
2019-10-17 |
2019-10-16 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
|
10 000
-61.6%
46,87
468 726 USD
|
10 000
-61.6%
|
46,87
|
468 726 USD
|
|
|
2019-10-17 |
2019-10-15 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10 595
-59.8%
46,89
496 769 USD
|
10 595
-59.8%
|
46,89
|
496 769 USD
|
|
|
2019-09-16 |
2019-09-16 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10 595
-59.8%
25,26
267 675 USD
|
10 595
-59.8%
|
25,26
|
267 675 USD
|
|
|
2019-09-16 |
2019-09-12 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
|
10 000
-61.6%
25,41
254 050 USD
|
10 000
-61.6%
|
25,41
|
254 050 USD
|
|
|
2019-08-27 |
2019-08-23 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
Dirigeant
|
2 285
-20.0%
27,89
63 740 USD
|
2 285
-20.0%
|
27,89
|
63 740 USD
|
|
|
2019-08-27 |
2019-08-23 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
Dirigeant
|
10 000
-61.6%
27,77
277 703 USD
|
10 000
-61.6%
|
27,77
|
277 703 USD
|
|
|
2019-08-27 |
2019-08-23 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
Dirigeant
|
10 595
-59.8%
27,77
294 226 USD
|
10 595
-59.8%
|
27,77
|
294 226 USD
|
|
|
2019-07-18 |
2019-07-17 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
|
10 000
-61.6%
32,95
329 479 USD
|
10 000
-61.6%
|
32,95
|
329 479 USD
|
|
|
2019-07-16 |
2019-07-15 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
4 216
-37.2%
33,29
140 338 USD
|
4 216
-37.2%
|
33,29
|
140 338 USD
|
|
|
2019-07-16 |
2019-07-15 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
6 379
-36.0%
32,97
210 309 USD
|
6 379
-36.0%
|
32,97
|
210 309 USD
|
|
|
2019-06-25 |
2019-06-21 |
VP
Vente planifiée
|
Ricardo Alonso
See Remarks
|
2 857
-20.0%
23,72
67 782 USD
|
2 857
-20.0%
|
23,72
|
67 782 USD
|
|
|
2019-06-19 |
2019-06-18 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
|
414
-6.2%
23,09
9 560 USD
|
414
-6.2%
|
23,09
|
9 560 USD
|
|
|
2019-06-19 |
2019-06-18 |
VP
Vente planifiée
|
Read Simon
Chief Scientific Officer
|
9 586
-59.0%
22,21
212 908 USD
|
9 586
-59.0%
|
22,21
|
212 908 USD
|
|
|
2019-06-19 |
2019-06-17 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
7 184
-50.2%
22,04
158 363 USD
|
7 184
-50.2%
|
22,04
|
158 363 USD
|
|
|
2019-06-19 |
2019-06-17 |
VP
Vente planifiée
|
Farzaneh-Far Ramin
Chief Medical Officer
|
3 411
-19.2%
21,41
73 021 USD
|
3 411
-19.2%
|
21,41
|
73 021 USD
|
|
|
2018-12-14 |
2018-12-14 |
A
Achat
|
Shah Rajeev M.
Administrateur non-exécutif
Actionnaire important
|
1 006 452
+26.1%
15,50
15 600 006 USD
|
1 006 452
+26.1%
|
15,50
|
15 600 006 USD
|
|
|
2018-12-14 |
2018-12-14 |
A
Achat
|
NEW ENTERPRISE ASSOCIATES 13 LP
Actionnaire important
|
645 161
+11.8%
15,50
9 999 996 USD
|
645 161
+11.8%
|
15,50
|
9 999 996 USD
|
|
|
2018-12-14 |
2018-12-12 |
A
Achat
|
RA CAPITAL MANAGEMENT, LLC
Administrateur non-exécutif
Actionnaire important
|
1 006 452
+26.1%
15,50
15 600 006 USD
|
1 006 452
+26.1%
|
15,50
|
15 600 006 USD
|
|
|
2018-02-21 |
2018-02-16 |
A
Achat
|
NEW ENTERPRISE ASSOCIATES 13 LP
Actionnaire important
|
2 000 000
+57.3%
6,00
12 000 000 USD
|
2 000 000
+57.3%
|
6,00
|
12 000 000 USD
|
|
|
2018-02-16 |
2018-02-14 |
A
Achat
|
RA CAPITAL MANAGEMENT, LLC
Administrateur non-exécutif
Actionnaire important
|
2 500 000
+184.9%
6,00
15 000 000 USD
|
2 500 000
+184.9%
|
6,00
|
15 000 000 USD
|
|
|
2018-02-16 |
2018-02-14 |
A
Achat
|
Shah Rajeev M.
Administrateur non-exécutif
Actionnaire important
|
2 500 000
+184.9%
6,00
15 000 000 USD
|
2 500 000
+184.9%
|
6,00
|
15 000 000 USD
|
|
|
2017-06-20 |
2017-06-19 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
3 220
-0.1%
22,02
70 899 USD
|
3 220
-0.1%
|
22,02
|
70 899 USD
|
|
|
2017-06-20 |
2017-06-16 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
53 200
-2.3%
21,24
1 130 207 USD
|
53 200
-2.3%
|
21,24
|
1 130 207 USD
|
|
|
2017-06-12 |
2017-06-08 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
700
-0.0%
22,00
15 400 USD
|
700
-0.0%
|
22,00
|
15 400 USD
|
|
|
2017-06-08 |
2017-06-07 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
4 840
-0.2%
22,11
106 999 USD
|
4 840
-0.2%
|
22,11
|
106 999 USD
|
|
|
2017-06-08 |
2017-06-06 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
7 274
-0.3%
22,98
167 161 USD
|
7 274
-0.3%
|
22,98
|
167 161 USD
|
|
|
2017-06-06 |
2017-06-05 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
4 780
-0.2%
23,11
110 488 USD
|
4 780
-0.2%
|
23,11
|
110 488 USD
|
|
|
2017-06-06 |
2017-06-02 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
14 867
-0.6%
23,47
348 949 USD
|
14 867
-0.6%
|
23,47
|
348 949 USD
|
|
|
2017-06-02 |
2017-06-01 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
10 722
-0.5%
23,89
256 176 USD
|
10 722
-0.5%
|
23,89
|
256 176 USD
|
|
|
2017-06-02 |
2017-05-31 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
35 539
-1.5%
23,94
850 896 USD
|
35 539
-1.5%
|
23,94
|
850 896 USD
|
|
|
2017-05-30 |
2017-05-26 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
5 300
-0.2%
25,14
133 267 USD
|
5 300
-0.2%
|
25,14
|
133 267 USD
|
|
|
2017-05-30 |
2017-05-25 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
53
-0.0%
25,00
1 325 USD
|
53
-0.0%
|
25,00
|
1 325 USD
|
|
|
2017-05-25 |
2017-05-24 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
17 451
-0.7%
25,01
436 364 USD
|
17 451
-0.7%
|
25,01
|
436 364 USD
|
|
|
2017-05-22 |
2017-05-18 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
9 019
-0.4%
25,50
229 964 USD
|
9 019
-0.4%
|
25,50
|
229 964 USD
|
|
|
2017-05-18 |
2017-05-17 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
22 534
-0.9%
25,51
574 901 USD
|
22 534
-0.9%
|
25,51
|
574 901 USD
|
|
|
2017-05-18 |
2017-05-16 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
20 081
-0.8%
26,33
528 725 USD
|
20 081
-0.8%
|
26,33
|
528 725 USD
|
|
|
2017-05-02 |
2017-03-01 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
7 778
-0.3%
20,91
162 658 USD
|
7 778
-0.3%
|
20,91
|
162 658 USD
|
|
|
2017-05-02 |
2017-02-28 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
7 847
-0.3%
20,86
163 670 USD
|
7 847
-0.3%
|
20,86
|
163 670 USD
|
|
|
2017-05-02 |
2017-02-27 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
57 844
-2.3%
20,96
1 212 306 USD
|
57 844
-2.3%
|
20,96
|
1 212 306 USD
|
|
|
2017-05-02 |
2017-02-24 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
5 398
-0.2%
20,93
113 000 USD
|
5 398
-0.2%
|
20,93
|
113 000 USD
|
|
|
2017-05-02 |
2017-02-23 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
4 999
-0.2%
21,04
105 160 USD
|
4 999
-0.2%
|
21,04
|
105 160 USD
|
|
|
2017-05-02 |
2017-02-22 |
V
Vente
|
Novartis Bioventures Ltd
Actionnaire important
|
749
-0.0%
21,86
16 370 USD
|
749
-0.0%
|
21,86
|
16 370 USD
|
|
|
2016-11-02 |
2016-10-31 |
A
Achat
|
Novo A/S
Actionnaire important
|
246 154
+13.8%
13,00
3 200 002 USD
|
246 154
+13.8%
|
13,00
|
3 200 002 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
SANDELL SCOTT D
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
SANDELL SCOTT D
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
KOLLURI KRISHNA KITTU
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
KOLLURI KRISHNA KITTU
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
MOTT DAVID M
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
MOTT DAVID M
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
MORGENTHALER VENTURE PARTNERS IX LP
Actionnaire important
|
263 538
+10.6%
13,00
3 425 994 USD
|
263 538
+10.6%
|
13,00
|
3 425 994 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
MORGENTHALER VENTURE PARTNERS IX LP
Actionnaire important
|
340
-0.4%
13,00
4 420 USD
|
340
-0.4%
|
13,00
|
4 420 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
Shah Rajeev M.
Administrateur non-exécutif
|
161 538
+13.6%
13,00
2 099 994 USD
|
161 538
+13.6%
|
13,00
|
2 099 994 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
RA CAPITAL MANAGEMENT, LLC
Administrateur non-exécutif
|
161 538
+13.6%
13,00
2 099 994 USD
|
161 538
+13.6%
|
13,00
|
2 099 994 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
BARRETT M JAMES
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
BARRETT M JAMES
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
Lettmann Jason
Administrateur non-exécutif
|
15 633
+0.4%
13,00
203 229 USD
|
15 633
+0.4%
|
13,00
|
203 229 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
Lettmann Jason
Administrateur non-exécutif
|
114 752
+2.9%
13,00
1 491 776 USD
|
114 752
+2.9%
|
13,00
|
1 491 776 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
Lettmann Jason
Administrateur non-exécutif
|
263 538
+7.2%
13,00
3 425 994 USD
|
263 538
+7.2%
|
13,00
|
3 425 994 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
Lettmann Jason
Administrateur non-exécutif
|
340
-0.4%
13,00
4 420 USD
|
340
-0.4%
|
13,00
|
4 420 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
BARRIS PETER J
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
BARRIS PETER J
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
KERINS PATRICK J
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Vente
|
KERINS PATRICK J
Actionnaire important
|
435
-0.5%
13,00
5 655 USD
|
435
-0.5%
|
13,00
|
5 655 USD
|
|
|
2016-10-31 |
2016-10-31 |
A
Achat
|
Weller Harry R
Actionnaire important
|
338 462
+10.7%
13,00
4 400 006 USD
|
338 462
+10.7%
|
13,00
|
4 400 006 USD
|
|
